Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
ASX reporting season wrap: BHP, banks, CSL bloodbath and more
stocks
Stock showdown: How do ASX healthcare giants compare on key investing criteria?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,234.30 | 55.70 | -0.60% |
CAC 40 | 7,969.69 | 31.40 | 0.40% |
DAX 40 | 24,363.09 | 69.75 | 0.29% |
Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,339.14 | 234.53 | 0.93% |
NASDAQ | 21,496.54 | 396.22 | 1.88% |
Nikkei 225 | 42,633.29 | 23.12 | 0.05% |
NZX 50 Index | 13,042.76 | 151.31 | -1.15% |
S&P 500 | 6,466.91 | 96.74 | 1.52% |
S&P/ASX 200 | 8,967.40 | 57.00 | -0.63% |
SSE Composite Index | 3,825.76 | 54.66 | 1.45% |